IFNG and neoplasm: Indeed, the authors clearly demonstrated that the combination of oxaliplatin with VE-822 (an ATR inhibitor) promoted an anti-tumor T-cell response which was characterized by an increased number of MC38-targeting IFNγ-producing CD8+ T-cells in mice that received the combined treatment compared to those treated with oxaliplatin alone [135].